Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLO-FAST: Clofazimine and Rifapentine for Drug-Susceptible Tuberculosis
NCT04311502Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of clofazimine and rifapentine in Tuberculosis (TB) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Time to 12 Weeks Stable Culture Conversion in Liquid Media and Participants Experiencing Any Grade 3 or Higher Adverse Event That is at Least a One Grade Increase From Baseline at 65 weeks. Started Nov 2021; status: terminated.
02
Drugs
clofaziminerifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04311502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311502.